Covered recipient · General Payments record
JUVENAL E MARTINEZ
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$1,714.64
78 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,714.64 | 78 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie Inc. | $249.18 | 22 |
| Biohaven Pharmaceuticals, Inc. | $244.74 | 2 |
| Gilead Sciences, Inc. | $174.24 | 2 |
| AstraZeneca Pharmaceuticals LP | $164.75 | 10 |
| Lilly USA, LLC | $158.21 | 10 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $158.18 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $144.34 | 3 |
| Amarin Pharma Inc. | $132.50 | 9 |
| Kowa Pharmaceuticals America, Inc. | $58.07 | 3 |
| GlaxoSmithKline, LLC. | $48.83 | 2 |
| Biogen, Inc. | $36.54 | 2 |
| Novo Nordisk Inc | $34.78 | 2 |
| Janssen Pharmaceuticals, Inc | $24.41 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $21.06 | 1 |
| IBSA Pharma Inc. | $17.41 | 1 |
| SANOFI-AVENTIS U.S. LLC | $16.48 | 1 |
| Eisai Inc. | $15.63 | 1 |
| Novartis Pharmaceuticals Corporation | $15.29 | 1 |
Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JUVENAL E MARTINEZ
NPI 1558459529 · CMS profile ID 69926
Allopathic & Osteopathic Physicians / Family Medicine
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1558459529?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558459529?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558459529?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 78 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1558459529?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
78 matching records · $1,714.64 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 78.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amarin Pharma Inc. | $20.00 | 12/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815387715 | CMS |
| Eisai Inc. | $15.63 | 12/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845776261 | CMS |
| Gilead Sciences, Inc. | $100.00 | 11/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848236301 | CMS |
| Lilly USA, LLC | $15.18 | 11/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818616675 | CMS |
| Amarin Pharma Inc. | $21.54 | 11/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815338943 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.93 | 11/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829819023 | CMS |
| AbbVie Inc. | $23.08 | 11/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523851 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $98.79 | 10/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826583685 | CMS |
| AbbVie Inc. | $4.09 | 10/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523845 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $21.06 | 10/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789063895 | CMS |
| AbbVie Inc. | $4.84 | 10/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523839 | CMS |
| Lilly USA, LLC | $15.00 | 10/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818617325 | CMS |
| AbbVie Inc. | $4.60 | 10/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523833 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.77 | 10/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829303855 | CMS |
| AbbVie Inc. | $4.17 | 10/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523829 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.76 | 10/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763738474 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $99.06 | 10/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820070479 | CMS |
| Amarin Pharma Inc. | $20.00 | 09/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815163825 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $21.85 | 09/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820070475 | CMS |
| Biohaven Pharmaceuticals, Inc. | $119.49 | 09/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852559911 | CMS |
| Kowa Pharmaceuticals America, Inc. | $20.17 | 09/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 805527241 | CMS |
| Gilead Sciences, Inc. | $74.24 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848236299 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.77 | 09/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829327457 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.82 | 08/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829462629 | CMS |
| Janssen Pharmaceuticals, Inc | $11.66 | 08/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788383477 | CMS |
| AbbVie Inc. | $3.96 | 08/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523823 | CMS |
| Amarin Pharma Inc. | $8.22 | 08/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815163817 | CMS |
| Lilly USA, LLC | $15.00 | 08/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 856542189 | CMS |
| Novo Nordisk Inc | $15.92 | 08/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810724043 | CMS |
| Amarin Pharma Inc. | $20.00 | 07/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815387717 | CMS |
| Kowa Pharmaceuticals America, Inc. | $22.50 | 07/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 805527237 | CMS |
| Amarin Pharma Inc. | $3.53 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815163821 | CMS |
| Biogen, Inc. | $18.41 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827773997 | CMS |
| AbbVie Inc. | $20.80 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523817 | CMS |
| AbbVie Inc. | $3.02 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523811 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.74 | 06/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763738476 | CMS |
| AbbVie Inc. | $20.00 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523805 | CMS |
| Biohaven Pharmaceuticals, Inc. | $125.25 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 852559909 | CMS |
| AbbVie Inc. | $4.17 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523799 | CMS |
| Novartis Pharmaceuticals Corporation | $15.29 | 05/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 813058967 | CMS |
| AbbVie Inc. | $20.65 | 05/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523795 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.54 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830286887 | CMS |
| Biogen, Inc. | $18.13 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 827773995 | CMS |
| AbbVie Inc. | $2.87 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523789 | CMS |
| AbbVie Inc. | $2.86 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523783 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.21 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829487041 | CMS |
| Lilly USA, LLC | $15.00 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818621503 | CMS |
| AbbVie Inc. | $4.18 | 04/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523777 | CMS |
| AbbVie Inc. | $20.92 | 04/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 795523771 | CMS |
| Kowa Pharmaceuticals America, Inc. | $15.40 | 03/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 805527233 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,400.63 | 16 |
| PY2025 | Principal investigator | $701,734.65 | 46 |
| PY2024 | Principal investigator | $1,015,383.57 | 140 |
| PY2023 | Principal investigator | $1,037,707.93 | 416 |
| PY2022 | Principal investigator | $88,070.01 | 24 |
| PY2021 | Principal investigator | $334,298.45 | 64 |
| PY2020 | Principal investigator | $148,277.65 | 26 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
62 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,124.00 | 12/22/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226087373 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,272.86 | 12/19/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513284 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,515.00 | 11/17/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226087356 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,000.00 | 11/12/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192099389 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,705.34 | 10/29/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513288 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,125.00 | 10/29/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192099394 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,000.00 | 10/29/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192099401 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,077.00 | 10/20/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226087307 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,181.00 | 10/06/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226087283 |
| Recipient | GlaxoSmithKline, LLC. | $113.85 | 09/10/2025 | Covered Recipient Physician | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192099374 |
| Recipient | GlaxoSmithKline, LLC. | $34.91 | 09/10/2025 | Covered Recipient Physician | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192099378 |
| Recipient | GlaxoSmithKline, LLC. | $103.36 | 09/10/2025 | Covered Recipient Physician | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192099407 |
| Recipient | GlaxoSmithKline, LLC. | $237.63 | 09/10/2025 | Covered Recipient Physician | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192149797 |
| Recipient | GlaxoSmithKline, LLC. | $37.40 | 09/10/2025 | Covered Recipient Physician | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192186531 |
| Recipient | GlaxoSmithKline, LLC. | $119.99 | 09/10/2025 | Covered Recipient Physician | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192186535 |
| Recipient | GlaxoSmithKline, LLC. | $20.94 | 09/10/2025 | Covered Recipient Physician | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192186544 |
| Recipient | GlaxoSmithKline, LLC. | $527.02 | 09/10/2025 | Covered Recipient Physician | A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST | No dispute reported | 06/30/2026 | 1192186546 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,482.00 | 09/03/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226087274 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $15,096.98 | 08/27/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513138 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,300.00 | 08/11/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226087255 |
| Principal investigator 1 | UCB SA | $13,322.88 | 07/31/2025 | Non-covered Recipient Entity Anchor Medical Research, Llc | A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE | No dispute reported | 06/30/2026 | 1246658748 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $29,881.56 | 07/16/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513142 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $60,757.00 | 07/16/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215513170 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,501.00 | 07/14/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226087226 |
| Recipient | GlaxoSmithKline, LLC. | $37.80 | 07/09/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192099353 |
| Recipient | GlaxoSmithKline, LLC. | $34.53 | 07/09/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192099361 |
| Recipient | GlaxoSmithKline, LLC. | $35.04 | 07/09/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192099367 |
| Recipient | GlaxoSmithKline, LLC. | $515.26 | 07/09/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192099384 |
| Recipient | GlaxoSmithKline, LLC. | $75.86 | 07/09/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192149801 |
| Recipient | GlaxoSmithKline, LLC. | $291.79 | 07/09/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192186522 |
| Recipient | GlaxoSmithKline, LLC. | $87.59 | 07/09/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192186527 |
| Recipient | GlaxoSmithKline, LLC. | $127.66 | 07/09/2025 | Covered Recipient Physician | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192186539 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,905.00 | 06/27/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085208 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,665.00 | 05/29/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085200 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $32,361.21 | 05/21/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513059 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,000.00 | 05/07/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085196 |
| Principal investigator 1 | PFIZER INC. | $1,800.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228722916 |
| Principal investigator 1 | PFIZER INC. | $275.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228789970 |
| Principal investigator 1 | PFIZER INC. | $15,990.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228791032 |
| Principal investigator 1 | PFIZER INC. | $2,500.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228791845 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228792032 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228792237 |
| Principal investigator 1 | PFIZER INC. | $450.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228792266 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228792368 |
| Principal investigator 1 | PFIZER INC. | $1,200.00 | 04/23/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH LLC | A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 1228792588 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,855.75 | 04/18/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513080 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $362.37 | 04/09/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513076 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $68,255.21 | 04/01/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513072 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $4,002.27 | 03/12/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215512970 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $21,706.55 | 03/12/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215512973 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,300.00 | 03/10/2025 | Non-covered Recipient Entity Anchor Medical Research Llc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226085175 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $4,180.43 | 02/03/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513022 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $83,604.98 | 02/03/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513026 |
| Principal investigator 1 | Amgen Inc. | $92,292.28 | 01/30/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH | A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) | No dispute reported | 06/30/2026 | 1246639133 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $230.00 | 01/24/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215512922 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,300.00 | 01/24/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215512927 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,279.00 | 01/24/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215512931 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $613.00 | 01/24/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215512935 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 01/24/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215512953 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,200.00 | 01/24/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215512958 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,717.00 | 01/24/2025 | Non-covered Recipient Entity Anchor Medical Research LLC | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) | No dispute reported | 06/30/2026 | 1215512962 |
| Principal investigator 1 | Amgen Inc. | $91,847.98 | 01/22/2025 | Non-covered Recipient Entity ANCHOR MEDICAL RESEARCH | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246639131 |